Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Tiotropium+Olodaterol;   Device: Spiolto Respimat;   Drug: Long-acting muscarinic antagonists (LAMAs);   Drug: Long-acting β2-agonists (LABAs) Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials